C248 - Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
Event Time: | Friday May 10, 2019 7:00 am to 9:00 am |
Topic(s): | MS and CNS Inflammatory Disease |
Director(s): | Aaron Miller MD, FAAN |
Description: | Clinical decision-making in MS has become increasingly complex with more than a dozen disease-modifying agents FDA approved, and still others used off-label. Recent changes in diagnostic criteria and phenotype classification increase the challenges. Assimilating and using this new information may be particularly difficult for neurologists who do not have the extensive experience of MS subspecialists. This course will address those challenges by using a novel, interactive format to engage the audience in answering the practical questions that arise in daily clinical practice. The format will consist of a series of brief case vignettes focused on specific and controversial issues involving clinical decision nodes. For each vignette, two MS experts will offer their opinions about the course of action and the moderator will add or elicit further commentary. The audience may express their own views, before and after the experts, using the audience response system. |
Completion Message: | Participants should better understand and select DMTs in various circumstances; better understand the use of the McDonald Criteria and their limitations, as well as the new phenotypic descriptions used for MS; and better understand a variety of social and other medical situations that impact the management of people with MS. |
CME Credits: | 2 |
Core Competencies: | Patient Care, Interpersonal and Communication Skills, Medical Knowledge, Practice-Based Learning and Improvement |
Start/End Time | Title | Faculty |
---|---|---|
7:00 AM - 7:05 AM | Introduction | Aaron E. Miller MD, FAAN |
7:05 AM - 9:00 AM | Discussion of Brief Case Vignettes | Myla D. Goldman MD, MSC, FAAN, Stephen Krieger MD, FAAN, Aaron E. Miller MD, FAAN |
Speaker | Disclosure |
---|---|
Myla D. Goldman, MD, MSC, FAAN | Dr. Goldman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Genzyme, Novartis Pharmaceuticals, Teva Neuroscience, RxMx, Celgene. Dr. Goldman has received research support from MedDay, Novartis Pharmaceuticals, PCORI, NMSS. |
Stephen Krieger, MD, FAAN | Dr. Krieger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, MedDay, Novartis, Teva, and TG Therapeutics, and non-promotional speaking with Biogen, EMD Serono, and Novartis. |
Aaron E. Miller, MD, FAAN | Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accordant Health Services (Caremark), Adamas, BiogenIdec, Celgene, Corrona, EMD Serono, Genzyme/Sanofi, Mallinckrodt, Mapi-Pharma, Novartis, and Roche/Genentech. Dr. Miller has received personal compensation in an editorial capacity for Continuum Audio. Dr. Miller has received research support from BiogenIdec, Genzyme/Sanofi, Mallickrodt, Novartis, Roche/Genentech, and MedDay. |
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
7:00 AM-9:00 AM |
---|
C7 -
Clinical Pearls in Autoimmune Neurology: Real World Cases
Stacey Clardy MD, PhD |
9:30 AM-11:30 AM |
C19 -
Multiple Sclerosis Overview I: Clinical Pearls
Mary Willis MD, FAAN |
1:30 PM-3:30 PM |
C29 -
Multiple Sclerosis Overview II: Clinical Advances
Scott Newsome DO, FAAN |
7:00 AM-9:00 AM |
---|
C44 -
Multiple Sclerosis Therapy: Symptom Management
Andrew Solomon MD, FAAN |
9:15 AM-12:00 PM |
Presidential Plenary Session
Natalia Rost MD, MPH, FAAN, FAHA |
11:30 AM-6:30 PM |
P1 -
Poster Session 1
|
1:00 PM-3:00 PM |
C49 -
Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease
Adam Quick MD, Ralph Jozefowicz MD, FAAN |
C56 -
Multiple Sclerosis Therapy: Disease-modifying Treatment I
Scott Newsome DO, FAAN |
S6 -
MS and CNS Inflammatory Disease: Clinical Considerations I
|
3:30 PM-5:30 PM |
C73 -
Multiple Sclerosis Therapy: Disease-modifying Treatment II
John Rose MD, FAAN |
7:00 AM-9:00 AM |
---|
C86 -
Neuromyelitis Optica Spectrum Disorders
Dean Wingerchuk MD, FAAN |
9:15 AM-12:00 PM |
Contemporary Clinical Issues Plenary Session
Randolph Marshall MD, FAAN |
11:30 AM-6:30 PM |
P2 -
Poster Session 2
|
1:00 PM-3:00 PM |
C100 -
Esclerosis Múltiple y Otras Enfermedades Inflamatorias Desmielinizantes y Autoinmunes del Sistema Nervioso Central (MS and Other Demyelinating Inflammatory and Autoimmune Central Nervous System Disorders)
Lilyana Amezcua MD, FAAN |
S12 -
Progressive Multiple Sclerosis
|
3:30 PM-5:30 PM |
S19 -
Child Neurology: Updates in Autism, Migraine, MS, and Stroke
|
7:00 AM-9:00 AM |
---|
C130 -
Diagnostic Pearls in Myelitis: a Case-based Approach
Eoin Flanagan MBBCh |
9:15 AM-11:30 AM |
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
11:30 AM-6:30 PM |
P3 -
Poster Session 3
|
1:00 PM-3:00 PM |
C142 -
Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS
Stacey Clardy MD, PhD |
N3 -
Neuroscience in the Clinic: Stem Cells
Antonio Omuro MD, Paul George MD, PhD, MSE |
S26 -
MS and CNS Inflammatory Disease: Clinical Considerations II
|
3:30 PM-5:30 PM |
C160 -
Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience
Eoin Flanagan MBBCh |
S31 -
MS and CNS Inflammatory Disease: Imaging
|
9:15 AM-11:30 AM |
---|
Frontiers in Neuroscience Plenary Session
Paul George MD, PhD, MSE |
11:30 AM-6:30 PM |
P4 -
Poster Session 4
|
1:00 PM-3:00 PM |
C181 -
Treatment of Pediatric Multiple Sclerosis in the Current Era
Brenda Banwell MD, FAAN |
S37 -
MS Biomarkers
|
3:30 PM-5:30 PM |
Presentation of the John Dystel Prize for Multiple Sclerosis Research
|
3:45 PM-4:15 PM |
Update on the Complementary Therapies for MS: An Evidence-based Review
Vijayshree Yadav MD, FAAN |
11:30 AM-6:30 PM |
---|
P5 -
Poster Session 5
|
12:00 PM-12:45 PM |
A "How to and Why" of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time
Nancy Isenberg MD, MPH, FAAN, Mary Rensel MD, FAAN |
1:00 PM-3:00 PM |
C226 -
Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I
Jeffrey Gelfand MD, MAS, FAAN |
S49 -
MS Epidemiology and Risk Stratification
|
3:30 PM-5:30 PM |
C236 -
Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II
Jeffrey Gelfand MD, MAS, FAAN |
S55 -
MS Basic Science
|
7:00 AM-9:00 AM |
---|
9:15 AM-11:30 AM |
Neurology Year in Review Plenary Session
Martinson Arnan MD |
1:00 PM-3:00 PM |
S56 -
MS Trials and Treatment
|
3:30 PM-4:30 PM |
C257 -
Education Blitz: Evolution of Autoimmune Neurology
Steven Vernino MD, PhD, FAAN |
C258 -
Education Blitz: Multiple Sclerosis
Stephen Krieger MD, FAAN |